Table 1.
Treatment | Dose (μg/plate) | TA100 |
TA1535 |
WP2 uvrA |
TA98 |
TA1537 |
|||||
---|---|---|---|---|---|---|---|---|---|---|---|
−S9 | +S9 | −S9 | +S9 | −S9 | +S9 | −S9 | +S9 | −S9 | +S9 | ||
Negative control | 0 | 91, 114 | 139, 132 | 9, 13 | 8, 13 | 23, 24 | 24, 24 | 19, 11 | 31, 26 | 7, 5 | 10, 11 |
KPFORCETM | 39.1 | 108, 123 | - | 7, 8 | - | - | - | - | - | 7, 7 | |
78.1 | 93, 97 | - | 4, 5 | - | - | - | - | - | 8, 4 | ||
156 | 104, 97 | 165, 169 | 11, 6 | 8, 6 | - | - | 16, 13 | 41, 26 | 4, 5 | 15, 15 | |
313 | 98, 107 | 162, 170 | 5, 7 | 12, 11 | 26, 24 | 25, 35 | 20, 17 | 50, 34 | 4, 5 | 10, 13 | |
625 | 75, 83 | 152, 176 | 5*, 7* | 10, 6 | 20, 15 | 36, 29 | 15, 18 | 36, 33 | 3*, 6* | 14, 18 | |
1250 | 44*, 68* | 161, 174 | 4*, 3* | 8, 10 | 16, 17 | 25, 28 | 17, 12 | 33, 28 | 1*, 1* | 18, 20 | |
2500 | - | 171, 160 | - | 4*, 5* | 16, 15 | 27, 19 | 19*, 19* | 27*, 25* | - | 7*, 9* | |
5000 | - | 95*, 110* | - | 4*, 3* | 18, 16 | 19, 15 | 19*, 12* | 35*, 25* | - | 6*, 5* | |
AF-2 | 0.01 | 571, 588 | - | - | - | 67, 62 | - | - | - | - | - |
0.1 | - | - | - | - | - | - | 321, 327 | - | - | - | |
NaN3 | 0.5 | - | - | 257, 273 | - | - | - | - | - | - | - |
ICR-191 | 1.0 | - | - | - | - | - | - | - | - | 1070, 1052 | - |
BαP | 5.0 | - | 892, 946 | - | - | - | - | - | 391, 427 | - | 95, 82 |
2AA | 2.0 | - | - | - | 305, 278 | - | - | - | - | - | - |
10.0 | - | - | - | - | - | 739, 878 | - | - | - | - |
Results are shown as means from two plates as indicated by the number of revertant colonies (n = 2).
Abbreviations: TA100, Salmonella typhimurium TA100; TA1535, Salmonella typhimurium TA1535; WP2 uvrA, Escherichia coli WP2 uvrA; TA98, Salmonella typhimurium TA98; TA1537, Salmonella typhimurium TA1537; AF-2, 2-(2-furyl)-3-(5-nitro-2-furyl) acrylamide; ICR-191, 2-methoxy-6-chloro-9-[3-(2-chloroethyl)aminopropylamino]-acridine dihydrochloride; BαP, benzo-[α]-pyrene; 2AA, 2-aminoanthracene.
Growth inhibition was observed.